Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AUTO2

Cell therapy (CAR-T) · Kills target cells · developed by Autolus

Phase 1/2 Most advanced trial (none active)

AUTL Developer

1 Registered trials

What is AUTO2?

AUTO2 is an autologous CAR T cell therapy in which T cells are engineered to carry an APRIL-based chimeric antigen receptor. It is studied in multiple myeloma after preconditioning with cyclophosphamide and fludarabine.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Mechanism: Kills target cells
Therapy area: Oncology
Developer: Autolus Limited (AUTL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03287804	Phase 1/2	Multiple Myeloma	Terminated	AUTL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

More from Autolus

Obecabtagene autoleucel FDA approved AUTO3 Phase 1/2 AUTO4 Phase 1/2

Sources

ClinicalTrials.gov NCT03287804

Updated Oct 11, 2026. Something wrong or missing? Report it on the AUTL page.

Follow AUTL, the company behind AUTO2

See AUTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AUTL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z